Krishnaraj S. Rathod PhD , Katrina Comer BSc , Oliver Casey-Gillman MSc , Lizzie Moore MSc , Sotiris Antoniou MRPharmS, MSc , Sadeer Fhadil MPharm , Paul Wright MPharm, MSc , Jennifer Mather BSc , Michelle C.T. Yick MD , Rohan Vyas MD , Roy B. Wang MD , Muhiddin A. Ozkor MD , Oliver P. Guttmann MD , Andreas Baumbach MD , R. Andrew Archbold MD , Andrew Wragg PhD , Ajay K. Jain MD , Fizzah A. Choudry PhD , Anthony Mathur PhD , Daniel A. Jones PhD
{"title":"Cost-Effectiveness of Early Discharge (<48 Hours) for Low-Risk Patients Following PPCI for STEMI","authors":"Krishnaraj S. Rathod PhD , Katrina Comer BSc , Oliver Casey-Gillman MSc , Lizzie Moore MSc , Sotiris Antoniou MRPharmS, MSc , Sadeer Fhadil MPharm , Paul Wright MPharm, MSc , Jennifer Mather BSc , Michelle C.T. Yick MD , Rohan Vyas MD , Roy B. Wang MD , Muhiddin A. Ozkor MD , Oliver P. Guttmann MD , Andreas Baumbach MD , R. Andrew Archbold MD , Andrew Wragg PhD , Ajay K. Jain MD , Fizzah A. Choudry PhD , Anthony Mathur PhD , Daniel A. Jones PhD","doi":"10.1016/j.jcin.2025.04.045","DOIUrl":"10.1016/j.jcin.2025.04.045","url":null,"abstract":"<div><h3>Background</h3><div>Early discharge after primary percutaneous coronary intervention can increase the efficiency of health care, enabling cost savings. Dedicated virtual follow-up pathways can provide remote diagnostic information to aid earlier discharge, optimize care and reduce unplanned readmissions.</div></div><div><h3>Objectives</h3><div>The aims of this study were: 1) to review the long-term (1-year) safety of early hospital discharge (<48 hours) after ST-segment elevation myocardial infarction; 2) to assess the effect of virtual follow-up on medication adherence and ability to up-titrate secondary prevention medication; and 3) to determine the cost-effectiveness of a virtual follow-up pathway after early discharge.</div></div><div><h3>Methods</h3><div>Between April 2020 and March 2023, 1,500 low-risk patients were discharged at <48 hours and placed on the early hospital discharge follow-up pathway. Patients were reviewed by structured virtual follow-up at 48 hours; 2, 4, and 8 weeks; and 3 and 12 months.</div></div><div><h3>Results</h3><div>The median length of hospital stay was 24.9 hours (Q1-Q3: 22.8-36.4 hours), with a minimum of 17 hours and a maximum of 40 hours. Seventy-three percent of patients (1,095 of 1,500) stayed 1 fewer night in the hospital compared with normal pathways. The median length of stay for the control group was 68.1 hours (Q1-Q3: 56-80 hours) (<em>P</em> < 0.0001). During 12-month follow-up, there was a low major adverse cardiac event rate of 3.1% (47 of 1,500) including 0.6% (9 of 1,500) for all-cause mortality and 0.13% (2 of 1,500) for cardiovascular mortality in the early hospital discharge group, which compared favorably with the >48-hour control group (major adverse cardiac event rate 5.5% [77 of 1,400]; <em>P</em> = 0.043).</div></div><div><h3>Conclusions</h3><div>Selected low-risk patients can be discharged securely and safely following successful primary percutaneous coronary intervention using a pathway that is reinforced by a formal, multidisciplinary virtual follow-up program, enabling improvements in medication adherence and up-titration.</div></div>","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 12","pages":"Pages 1499-1509"},"PeriodicalIF":11.7,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144365470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"15-Year Outcomes of PFO Closure in Patients With Cryptogenic Embolism","authors":"Carlo Gaspardone MD , Daniela Trabattoni MD , Daniele O. d’Atri MD , Michele Morosato MD , Paolo Costa MD , Chiara Fraccaro MD, PhD , Andrea Donti MD , Francesco Saia MD, PhD , Evelina Toscano MD , Filippo Scalise MD , Alessio Cucco MD , Giuseppe Patti MD , Roberto Nerla MD , Fausto Castriota MD , Carlo Trani MD , Riccardo Improta MD , Massimo Mancone MD, PhD , Gennaro Sardella MD , Carmine Musto MD, PhD , Maurizio Paciaroni MD , Cosmo Godino MD","doi":"10.1016/j.jcin.2025.04.041","DOIUrl":"10.1016/j.jcin.2025.04.041","url":null,"abstract":"<div><h3>Background</h3><div>Transcatheter patent foramen ovale (PFO) closure has become the gold-standard treatment for patients with cryptogenic embolism and PFO, but long-term outcomes data are limited.</div></div><div><h3>Objectives</h3><div>The aim of this study was to report the extended clinical outcomes of patients who underwent transcatheter PFO closure for cryptogenic embolism.</div></div><div><h3>Methods</h3><div>PROLONG (PFO Transcatheter Occlusion Long-Term Outcomes National Group) is an investigator-initiated, multicenter, retrospective registry that enrolled patients who underwent transcatheter PFO closure between 1999 and 2013 at 12 centers in Italy. This analysis included only patients who underwent PFO closure for cryptogenic embolism, defined as cryptogenic ischemic stroke, transient ischemic attack, systemic embolism, or silent ischemic lesions on magnetic resonance imaging. Clinical, imaging, procedural, and follow-up data were collected from electronic health records and telephone interviews.</div></div><div><h3>Results</h3><div>The study included 1,245 patients (mean age 47 ± 12 years, 56% women), with a mean follow-up duration of 14.5 ± 2.4 years. During follow-up, 34 patients (2.7%) experienced recurrent ischemic stroke, transient ischemic attack, or systemic embolism (0.19 per 100 patient-years). Predictors of recurrent events were Risk of Paradoxical Embolism (RoPE) score ≤ 7 (HR: 3.44; 95% CI: 1.06-11.3; <em>P</em> = 0.041), nonprobable PFO-Associated Stroke Causal Likelihood (PASCAL) classification (HR: 2.72; 95% CI: 1.17-6.34; <em>P</em> = 0.020), and new-onset atrial fibrillation (HR: 7.01; 95% CI: 2.45-20.1; <em>P</em> < 0.001). Serious complications were rare (0.4% in hospital, 0.4% during follow-up) and nonfatal.</div></div><div><h3>Conclusions</h3><div>This study confirms the long-term efficacy and safety of transcatheter PFO closure for patients with cryptogenic embolism and PFO in a real-world setting. (PFO Transcatheter Occlusion Long-Term Outcomes National Group [PROLONG] Registry; <span><span>NCT06504121</span><svg><path></path></svg></span>)</div></div>","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 12","pages":"Pages 1526-1537"},"PeriodicalIF":11.7,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144365474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Too Soon to Go Home After a STEMI?","authors":"Christian Spaulding MD, PhD , Tanios Akiki MD","doi":"10.1016/j.jcin.2025.05.015","DOIUrl":"10.1016/j.jcin.2025.05.015","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 12","pages":"Pages 1510-1511"},"PeriodicalIF":11.7,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144365471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prosthesis-Patient Mismatch in Young and Low-Risk Patients After Newer Generation Balloon-Expandable Transcatheter Aortic Valve Replacement","authors":"Kazuki Suruga MD , Vivek Patel MS , Takashi Nagasaka MD , Yuchao Guo MD , Prateek Madaan MD , Ofir Koren MD , Dhairya Patel MPH , Izabela Harutyunyan MSN , Aakriti Gupta MD , Tarun Chakravarty MD , Wen Cheng MD , Hasan Jilaihawi MD , Mamoo Nakamura MD , Raj R. Makkar MD","doi":"10.1016/j.jcin.2025.05.003","DOIUrl":"10.1016/j.jcin.2025.05.003","url":null,"abstract":"<div><h3>Background</h3><div>The clinical impact of prosthesis-patient mismatch (PPM) after transcatheter aortic valve replacement (TAVR) is not well known in young and low-risk patients.</div></div><div><h3>Objectives</h3><div>The aim of this single-center study was to evaluate the incidence, predictors, and long-term impact of PPM in young and low-risk patients with severe native aortic stenosis (AS) following TAVR.</div></div><div><h3>Methods</h3><div>From August 2015 to December 2022, a total of 3,549 patients underwent TAVR with newer generation balloon-expandable valves. Among them, 512 patients with severe native AS who were younger than 75 years and had Society of Thoracic Surgeons scores <4% were included. All-cause and cardiovascular mortality or heart failure hospitalization during follow-up period were compared between the PPM and non-PPM groups. PPM was defined according to the Valve Academic Research Consortium-3 criteria.</div></div><div><h3>Results</h3><div>PPM was observed in 200 of 512 patients (39.0%), with moderate and severe PPM in 162 of 512 (31.6%) and 38 of 512 (7.4%), respectively. Younger age, female sex, larger body surface area, no balloon postdilation, and smaller annular area were independent predictors of PPM. Over a median follow-up duration of 1,034 days (Q1-Q3: 550-1,567 days), compared with the non-PPM group, the PPM group had significantly higher all-cause mortality (HR: 2.55; 95% CI: 1.3-5.0; <em>P</em> = 0.007), cardiovascular mortality (HR: 2.81; 95% CI: 1.1-7.5; <em>P</em> = 0.04), and heart failure hospitalization (HR: 4.43; 95% CI: 2.0-9.9; <em>P</em> < 0.001).</div></div><div><h3>Conclusions</h3><div>PPM is associated with worse clinical outcomes in young and low-risk patients with AS after TAVR, even with newer generation balloon-expandable valves.</div></div>","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 12","pages":"Pages 1512-1523"},"PeriodicalIF":11.7,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144365472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gennaro Giustino MD , Konstantinos Koulogiannis MD , Lawrence Blitz MD , Benjamin van Boxtel MD , Barry Cohen MD , Pedro Villablanca MD , Linda Gillam MD , John Brown III MD , Robert Kipperman MD , Philippe Genereux MD
{"title":"First-in-Human Percutaneous Transseptal Retrieval of Embolized Transcatheter Valve in the Left Ventricle","authors":"Gennaro Giustino MD , Konstantinos Koulogiannis MD , Lawrence Blitz MD , Benjamin van Boxtel MD , Barry Cohen MD , Pedro Villablanca MD , Linda Gillam MD , John Brown III MD , Robert Kipperman MD , Philippe Genereux MD","doi":"10.1016/j.jcin.2025.03.011","DOIUrl":"10.1016/j.jcin.2025.03.011","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 12","pages":"Pages 1591-1594"},"PeriodicalIF":11.7,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144010242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"How Does the TAVR Universe Best Expand?","authors":"Sachin S. Goel MD , Michael J. Reardon MD","doi":"10.1016/j.jcin.2025.03.035","DOIUrl":"10.1016/j.jcin.2025.03.035","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 12","pages":"Pages 1569-1570"},"PeriodicalIF":11.7,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144365349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}